(3) The effectiveness of the guidelines referred
to in section 2.
(b) REPORT.—Not later than 5 years after the date
of the enactment of this Act, the Director of the National
Institutes of Health shall submit a report describing the
findings and conclusions of the study to the Committee
on Energy and Commerce of the House of Representatives
and the Committee on Health, Education, Labor, and
Pensions of the Senate.
SEC. 
4. 
STUDY 
ON 
THERAPIES 
ADDRESSING
IMMUNOLOGICAL 
REJECTION 
OF 
STEM
CELLS AND DIFFERENTIATED CELLS AND
TISSUE DERIVED FROM STEM CELLS.
(a) IN GENERAL.—The Secretary of Health and
Human Services (in this section referred to as the ‘‘Sec-
retary’’) shall seek to enter into an agreement with the
Institute of Medicine under which the Institute, taking
into consideration the results of the study authorized by
section 3, will conduct a study to—
(1) assess the current state of knowledge about
therapies, including somatic cell nuclear transfer and
therapies using pharmaceuticals, that may be used
to address immunological rejection of stem cells and
differentiated cells and tissue derived from stem
cells;
(2) compare the potential therapeutic value of
such therapies; and
(3) identify safeguards that could be imple-
mented to prevent the use of human embryos cre-
ated by somatic cell nuclear transfer for purposes
other than the development of therapies for diseases.
(b) OTHER ENTITIES.—If the Institute of Medicine
declines to conduct the study described in subsection (a),
the Secretary shall enter into an agreement with another
appropriate public or nonprofit private entity to conduct
the study.
(c) REPORT.—The Secretary shall ensure that, not
later than 2 years after the date of the enactment of this
Act, the study to be conducted under subsection (a) is
completed and a report describing the findings and conclu-
sions of the study is submitted to the Committee on En-
ergy and Commerce of the House of Representatives and
the Committee on Health, Education, Labor, and Pen-
sions of the Senate.
SEC. 5. BIOMEDICAL ADVISORY COMMISSION.
(a) ESTABLISHMENT.—There is established a com-
mission to be known as the Biomedical Advisory Commis-
sion (in this section referred to as the ‘‘Commission’’).
(b) DUTIES.—
(1) STUDY.—The Commission shall conduct
studies on the following:
(A) Bioethical issues arising from research
on human biology and applications of such re-
search.
(B) Emerging biomedical research, includ-
ing the ethical, social, legal, and regulatory
issues concerning such research and its clinical
applications.
(2) RECOMMENDATIONS.—Based on the results
of the study, the Commission shall formulate such
recommendations as it considers appropriate with
the goal of realizing the development of effective
therapies as quickly as possible, taking into account
the relevant ethical, social, legal, and regulatory con-
siderations.
(c) MEMBERSHIP.—
(1) APPOINTMENT.—The Commission shall be
composed of 13 members as follows:
(A) 1 member appointed by the President.
(B) 3 members appointed by the Speaker
of the House of Representatives.
(C) 3 members appointed by the minority
leader of the House of Representatives.
(D) 3 members appointed by the majority
leader of the Senate.
(E) 3 members appointed by the minority
leader of the Senate.
(2) QUALIFICATIONS.—The members appointed
under subparagraphs (B), (C), (D), and (E) of para-
graph (1) shall include representatives from the
legal, ethical, scientific, medical, patient, religious,
and industry communities.
(3) CONSULTATION.—All appointments under
paragraph (1) shall be made in consultation with
members of the communities referred to in para-
graph (2).
(4) CHAIRPERSON.—The Chairperson of the
Commission shall be elected by a majority from
among the members of the Commission.
(5) TERMS.—Each member of the Commission
shall be appointed for a term of 3 years and may be
reappointed.
(6) VACANCIES.—A vacancy in the Commission
shall be filled in the manner in which the original
appointment was made.
(d) MEETINGS.—The Commission shall meet—
(1) at the call of the Chairperson; and
(2) at least 2 times but not more than 4 times
each calendar year.
(e) COMPENSATION AND EXPENSES.—
(1) COMPENSATION.—Subject to paragraph (2),
each member of the Commission shall be com-
pensated at a rate equal to the daily equivalent of
the annual rate of basic pay prescribed for level III
of the Executive Schedule under section 5314 of title
5, United States Code, for each day (including travel
time) during which such member is engaged in the
performance of the duties of the Commission.
(2) PROHIBITION OF COMPENSATION OF FED-
ERAL
EMPLOYEES.—Members of the Commission
who are full-time officers or employees of the United
States or Members of Congress may not receive ad-
ditional pay, allowances, or benefits by reason of
their service on the Commission.
(3) TRAVEL EXPENSES.—Each member of the
Commission shall receive travel expenses, including
per diem in lieu of subsistence, in accordance with
applicable provisions under subchapter I of chapter
57 of title 5, United States Code, while away from
the member’s home or regular place of business in
the performance of services for the Commission.
(f) EXECUTIVE DIRECTOR AND STAFF.—
(1) EXECUTIVE DIRECTOR.—
(A) 
APPOINTMENT.—The 
Commission
shall have an Executive Director who shall be
appointed by the Secretary of Health and
Human Services.
(B) PAY.—The Executive Director shall be
paid at a rate not to exceed the rate payable for
level V of the Executive Schedule under section
5316 of title 5, United States Code.
(2) STAFF.—
(A) APPOINTMENT.—The Executive Direc-
tor may appoint such additional personnel as
the Executive Director sees fit.
(B) PAY.—The staff of the Commission
shall be paid in accordance with the provisions
of chapter 51 and subchapter III of chapter 53
of title 5, United States Code, relating to classi-
fication and General Schedule pay rates.
(3) APPLICABILITY OF CERTAIN CIVIL SERVICE
LAWS.—The Executive Director and staff of the
Commission shall be appointed subject to the provi-
sions of title 5, United States Code, governing ap-
pointments in the competitive service.
(g) HEARINGS
AND SESSIONS.—The Commission
may, for the purpose of carrying out this section, hold
(l) TERMINATION.—The Commission terminates 30
days after the date that is 6 years after the date of the
enactment of this Act.
Æ